8,738 reports of this reaction
15.3% of all CINACALCET HYDROCHLORIDE reports
#1 most reported adverse reaction
DRUG DOSE OMISSION is the #1 most commonly reported adverse reaction for CINACALCET HYDROCHLORIDE, manufactured by Amgen Inc. There are 8,738 FDA adverse event reports linking CINACALCET HYDROCHLORIDE to DRUG DOSE OMISSION. This represents approximately 15.3% of all 57,261 adverse event reports for this drug.
Patients taking CINACALCET HYDROCHLORIDE who experience drug dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG DOSE OMISSION is a frequently reported adverse event for CINACALCET HYDROCHLORIDE, accounting for a significant proportion of all reports.
In addition to drug dose omission, the following adverse reactions have been reported for CINACALCET HYDROCHLORIDE:
The following drugs have also been linked to drug dose omission in FDA adverse event reports:
DRUG DOSE OMISSION has been reported as an adverse event in 8,738 FDA reports for CINACALCET HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG DOSE OMISSION accounts for approximately 15.3% of all adverse event reports for CINACALCET HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience drug dose omission while taking CINACALCET HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.